Cell-specific CD39 expression in macrophages then cooperates with the CD73 specifically expressed in HCC cells to participate in the activation of the ATP-adenosine pathway, and the increase in adenosine ultimately promotes HCC progression and limites the anti-PD1 therapy response. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.